Alzamend Neuro: Ascendiant Capital Maintains Buy, PT Down to $42 from $45

Alzamend Neuro: Ascendiant Capital Maintains Buy, PT Down to $42 from $45

Wall Street securities analysts have revised their ratings and price targets on several U.S.-listed companies, according to Reuters. The changes, reported on Thursday, include notable updates for Apogee Therapeutics, Intel, and Northern Trust.

Apogee Therapeutics (APGE)
- RBC Capital Markets initiated coverage with an outperform rating and set a price target of $60 Apogee Therapeutics, Intel, Northern Trust^[1].

Intel (INTC)
- Seaport Research Partners raised its rating to neutral from sell Apogee Therapeutics, Intel, Northern Trust^[1].

Northern Trust Corp (NTRS)
- TD Cowen initiated coverage with a buy rating and set a price target of $152 Apogee Therapeutics, Intel, Northern Trust^[1].

Other notable changes include:
- Acadia Pharmaceuticals Inc (ACAD): Deutsche Bank and TD Cowen both revised their target prices Apogee Therapeutics, Intel, Northern Trust^[1].
- Alzamend Neuro Inc (ALZN): Ascendiant Capital Markets cut its price target to $42 from $45 Apogee Therapeutics, Intel, Northern Trust^[1].
- Atlantic Union Bankshares Corp (AUB): TD Cowen initiated coverage with a buy rating and set a price target of $46 Apogee Therapeutics, Intel, Northern Trust^[1].
- Bank Ozk (OZK), Cullen/Frost Bankers Inc (CFR), Customers Bancorp Inc (CUBI), and many others received new coverage or target price revisions Apogee Therapeutics, Intel, Northern Trust^[1].

Reference List:
Apogee Therapeutics, Intel, Northern Trust^[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L3N3VC0H3:0-apogee-therapeutics-intel-northern-trust/